MoneyWorks4Me

Lupin informs about press release

26 May 2025 Evaluate
Lupin has informed that it enclosed a Press Release as regards, the Company has entered into a license and supply agreement with SteinCares, a leading specialty healthcare company in Latin America, for commercialization of Lupin’s biosimilar ranibizumab across Latin America excluding Mexico and Argentina.

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2174.40 -15.60 (-0.71%)
25-Aug-2026 11:47 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1917.00
Dr. Reddys Labs. 1186.70
Cipla 1419.40
Lupin 2174.40
Zydus Lifesciences 1096.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: